259 related articles for article (PubMed ID: 29729898)
1. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1).
Meesilpavikkai K; Dik WA; Schrijver B; Nagtzaam NMA; Posthumus-van Sluijs SJ; van Hagen PM; Dalm VASH
J Allergy Clin Immunol; 2018 Jul; 142(1):328-330.e2. PubMed ID: 29729898
[No Abstract] [Full Text] [Related]
2. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.
Higgins E; Al Shehri T; McAleer MA; Conlon N; Feighery C; Lilic D; Irvine AD
J Allergy Clin Immunol; 2015 Feb; 135(2):551-3. PubMed ID: 25662309
[No Abstract] [Full Text] [Related]
3. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1.
Carey B; Lambourne J; Porter S; Hodgson T
Oral Dis; 2019 Apr; 25(3):684-692. PubMed ID: 29702748
[TBL] [Abstract][Full Text] [Related]
4. Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M; Kanderová V; Paračková Z; Vrabcová P; Svatoň M; Froňková E; Fejtková M; Zachová R; Rataj M; Zentsová I; Milota T; Klocperk A; Kalina T; Šedivá A
J Clin Immunol; 2018 Jul; 38(5):589-601. PubMed ID: 29934865
[TBL] [Abstract][Full Text] [Related]
5. STAT1 gain-of-function and chronic demodicosis.
Molho-Pessach V; Meltser A; Kamshov A; Ramot Y; Zlotogorski A
Pediatr Dermatol; 2020 Jan; 37(1):153-155. PubMed ID: 31637766
[TBL] [Abstract][Full Text] [Related]
6. The pathogenic T387A missense mutation in the gene encoding signal transducer and activator of transcription 1 exhibits a differential gene expression profile.
Staab J; Schwämmle T; Meyer T
Mol Immunol; 2020 Dec; 128():79-88. PubMed ID: 33096415
[TBL] [Abstract][Full Text] [Related]
7. Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors.
Borgström EW; Edvinsson M; Pérez LP; Norlin AC; Enoksson SL; Hansen S; Fasth A; Friman V; Kämpe O; Månsson R; Estupiñán HY; Wang Q; Ziyang T; Lakshmikanth T; Smith CIE; Brodin P; Bergman P
J Clin Immunol; 2023 Jan; 43(1):136-150. PubMed ID: 36050429
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Disseminated
Chen K; Tan J; Qian S; Wu S; Chen Q
Front Immunol; 2021; 12():682350. PubMed ID: 34421897
[TBL] [Abstract][Full Text] [Related]
9. The potential role for topical imiquimod in the treatment of chronic mucocutaneous candidiasis caused by gain-of-function mutation in STAT1: A case-report.
Reis J; van de Veerdonk FL; Carvalho A; Fernandes A; Machado S
Dermatol Ther; 2021 Sep; 34(5):e15043. PubMed ID: 34176198
[No Abstract] [Full Text] [Related]
10. Utility of ruxolitinib in a patient with chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation.
Olivier N; Boralevi F; Fricain JC; Doutre MS
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):e899-e902. PubMed ID: 35696308
[No Abstract] [Full Text] [Related]
11. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.
Depner M; Fuchs S; Raabe J; Frede N; Glocker C; Doffinger R; Gkrania-Klotsas E; Kumararatne D; Atkinson TP; Schroeder HW; Niehues T; Dückers G; Stray-Pedersen A; Baumann U; Schmidt R; Franco JL; Orrego J; Ben-Shoshan M; McCusker C; Jacob CM; Carneiro-Sampaio M; Devlin LA; Edgar JD; Henderson P; Russell RK; Skytte AB; Seneviratne SL; Wanders J; Stauss H; Meyts I; Moens L; Jesenak M; Kobbe R; Borte S; Borte M; Wright DA; Hagin D; Torgerson TR; Grimbacher B
J Clin Immunol; 2016 Jan; 36(1):73-84. PubMed ID: 26604104
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation.
Moriya K; Suzuki T; Uchida N; Nakano T; Katayama S; Irie M; Rikiishi T; Niizuma H; Okada S; Imai K; Sasahara Y; Kure S
Int J Hematol; 2020 Aug; 112(2):258-262. PubMed ID: 32180118
[TBL] [Abstract][Full Text] [Related]
13. Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib.
Dotta L; Todaro F; Baronio M; Giacomelli M; Pinelli M; Giambarda M; Brognoli B; Greco S; Rota F; Cortesi M; Soresina A; Moratto D; Tomasi C; Ferraro RM; Giliani S; Badolato R
J Clin Immunol; 2024 Apr; 44(4):85. PubMed ID: 38578354
[TBL] [Abstract][Full Text] [Related]
14. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
Forbes LR; Vogel TP; Cooper MA; Castro-Wagner J; Schussler E; Weinacht KG; Plant AS; Su HC; Allenspach EJ; Slatter M; Abinun M; Lilic D; Cunningham-Rundles C; Eckstein O; Olbrich P; Guillerman RP; Patel NC; Demirdag YY; Zerbe C; Freeman AF; Holland SM; Szabolcs P; Gennery A; Torgerson TR; Milner JD; Leiding JW
J Allergy Clin Immunol; 2018 Nov; 142(5):1665-1669. PubMed ID: 30092289
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.
Meesilpavikkai K; Dik WA; Schrijver B; van Helden-Meeuwsen CG; Versnel MA; van Hagen PM; Bijlsma EK; Ruivenkamp CAL; Oele MJ; Dalm VASH
Arthritis Rheumatol; 2019 May; 71(5):829-831. PubMed ID: 30666809
[No Abstract] [Full Text] [Related]
16. [Chronic mucocutaneous candidiasis with STAT1 gain-of-function mutation associated with herpes virus and mycobacterial infections].
Baghad B; Benhsaien I; El Fatoiki FZ; Migaud M; Puel A; Chiheb S; Bousfiha AA; Ailal F
Ann Dermatol Venereol; 2020 Jan; 147(1):41-45. PubMed ID: 31677808
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding.
Frans G; Moens L; Schaballie H; Van Eyck L; Borgers H; Wuyts M; Dillaerts D; Vermeulen E; Dooley J; Grimbacher B; Cant A; Declerck D; Peumans M; Renard M; De Boeck K; Hoffman I; François I; Liston A; Claessens F; Bossuyt X; Meyts I
J Allergy Clin Immunol; 2014 Nov; 134(5):1209-13.e6. PubMed ID: 25042743
[No Abstract] [Full Text] [Related]
18. Treatment options for chronic mucocutaneous candidiasis.
van de Veerdonk FL; Netea MG
J Infect; 2016 Jul; 72 Suppl():S56-60. PubMed ID: 27161991
[TBL] [Abstract][Full Text] [Related]
19. Human STAT1 gain-of-function iPSC line from a patient suffering from chronic mucocutaneous candidiasis.
Haake K; Wüstefeld T; Merkert S; Lüttge D; Göhring G; Auber B; Baumann U; Lachmann N
Stem Cell Res; 2020 Mar; 43():101713. PubMed ID: 32000109
[TBL] [Abstract][Full Text] [Related]
20. Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib.
Al Shehri T; Gilmour K; Gothe F; Loughlin S; Bibi S; Rowan AD; Grainger A; Mohanadas T; Cant AJ; Slatter MA; Hambleton S; Lilic D; Leahy TR
J Clin Immunol; 2019 Nov; 39(8):776-785. PubMed ID: 31512162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
